The new therapeutic modalities for the treatment of type 2 diabetes mellitus: insulin detemir added to liraglutide

Abstract

he literature data on the effectiveness and safety of the essentially new scheme of hypoglycemic therapy of type 2 diabetes mellitus are presented, The large-scale 52 week study has demonstrated that the addition of insulin detemir to the preceding treatment with liraglutide makes it possible to reach and maintain glycated hemoglobin percentage at the desired level of 7% in 43% of the patients. The risk of development of hypoglycemia was estimated at 0.286 episodes per patient per year in the absence of body weight increment. The combination of these two medications was found to produce pronounced hypoglycemic effect without affecting the pharmacokinetic properties of each other.